Moderna's Flu Vaccine Clears a Regulatory Hurdle

A swift FDA reversal puts Moderna's mRNA flu shot back on track and sharpens the regulatory playbook for RNA developers

12 Mar 2026

After a brief but embarrassing stumble, Moderna's bid to bring mRNA technology into the seasonal flu vaccine market is back on course. The American Food and Drug Administration, having sent the company a refusal-to-file letter on February 3rd, agreed just weeks later to review a revised submission for mRNA-1010, with a decision targeted for August 5th, 2026.

The initial rejection was not a safety warning. Regulators took issue with how the vaccine had been tested, specifically whether the comparator used in trials was appropriate for adults aged 65 and older. It was a methodological rebuke in a crowded, competitive market where flu vaccines must now prove themselves against well-established rivals. The FDA, it seems, is applying a sharper eye to study design even where the underlying science is not in doubt.

Moderna had announced its United States filing in January, alongside submissions in several overseas markets, aiming to extend mRNA technology beyond covid-19 into seasonal influenza for adults 50 and older. After the setback, the company rewrote its regulatory approach. It split the application by age group: seeking standard approval for adults aged 50 to 64, and accelerated approval for those 65 and older, backed by a commitment to post-marketing studies.

The result is that mRNA-1010 remains in contention for launch ahead of the 2026 to 2027 flu season. Whether it ultimately succeeds will depend on whether the revised filing satisfies regulators on the comparator question. But the episode carries a wider lesson for a sector that has grown accustomed to emergency shortcuts. mRNA platforms built their reputation on speed and scientific agility. That advantage counts for little if the regulatory paperwork does not hold up. In mature vaccine markets, process matters as much as platform.